REPLIGEN CORP

For the period ended Mar 31, 2025. Filed Apr 29, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed Apr 29, 2025

RGEN$173.49+3.0%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024 (Unaudited)

ANCE SHEETS

(Unaudited, amounts in thousands, except share data)

	March 31,	December 31,
	2025	2024
ASSETS
Current assets:
Cash and cash equivalents	$697,229	$757,355
Accounts receivable, net of reserves of $2,113 and $1,832 at March 31, 2025 and December 31, 2024, respectively	147,413	134,115
Inventories, net	153,110	142,964
Prepaid expenses and other current assets	34,713	31,607
Total current assets	1,032,465	1,066,041
Noncurrent assets:
Property, plant and equipment, net	195,519	197,738
Intangible assets, net	409,225	397,897
Goodwill	1,082,413	1,030,995
Deferred tax assets	737	749
Operating lease right of use assets	129,671	135,378
Other noncurrent assets	2,113	868
Total noncurrent assets	1,819,678	1,763,625
Total assets	$2,852,143	$2,829,666
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$26,935	$32,134
Operating lease liability	15,154	15,104
Current contingent consideration	33,865	17,126
Accrued liabilities	76,042	62,423
Total current liabilities	151,996	126,787
Noncurrent liabilities:
Convertible Senior Notes due 2028, net	529,605	525,567
Deferred tax liabilities	24,136	22,775
Noncurrent operating lease liability	138,939	145,576
Noncurrent contingent consideration	4,903	19,662
Other noncurrent liabilities	17,081	16,581
Total noncurrent liabilities	714,664	730,161
Total liabilities	866,660	856,948
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	—	—
Common stock, $0.01 par value; 80,000,000 shares authorized; 56,179,127 shares at March 31, 2025 and 56,091,677 shares at December 31, 2024 issued and outstanding	562	561
Additional paid-in capital	1,619,578	1,617,336
Accumulated other comprehensive loss	(47,841)	(52,533)
Retained earnings	413,184	407,354
Total stockholders’ equity	1,985,483	1,972,718
Total liabilities and stockholders’ equity	$2,852,143	$2,829,666

Condensed CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, amounts in thousands, except share and per share data)

	Three Months Ended March 31,
	2025	2024
Revenue:
Product	$169,137	$153,146
Royalty and other revenue	35	36
Total revenue	169,172	153,182
Costs and operating expenses:
Cost of goods sold	78,415	76,391
Research and development	12,924	11,238
Selling, general and administrative	71,255	61,803
Total costs and operating expenses	162,594	149,432
Income from operations	6,578	3,750
Other income (expenses):
Investment income	7,314	8,993
Interest expense	(5,250)	(5,029)
Amortization of debt issuance costs	(413)	(483)
Other expenses, net	(286)	(3,536)
Other income (expenses), net	1,365	(55)
Income before income taxes	7,943	3,695
Income tax provision	2,113	399
Net income	$5,830	$3,296
Earnings per share:
Basic	$0.10	$0.06
Diluted (Note 13)	$0.10	$0.06
Weighted average common shares outstanding:
Basic	56,123	55,791
Diluted (Note 13)	56,558	56,531
Net income	$5,830	$3,296
Other comprehensive income (loss):
Foreign currency translation adjustment	4,692	(5,134)
Comprehensive income (loss)	$10,522	$(1,838)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.